Immuvera Therapeutics is developing a new drug to treat cancer in the lungs, a highly burdensome form of cancer with a fatal outcome. The company’s first product is based on the BCG vaccine, which is currently used to treat bladder cancer in humans. Immuvera Therapeutics has adapted the vaccine for use in the lungs and for veterinary medicine, initially in dogs. The dog’s lung tissue is treated locally, stimulating the immune system to attack cancer cells. The treatment is gentle and has the potential for high efficacy.

The company has now completed a share issue via Folkeinvest, raising just under NOK 7.7 million. The share issue values the company at NOK 135 million post-money. More than 250 investors participated in the offering.

“We are very pleased that so many new shareholders have recognized the company’s potential,” says Jørund Sollid, CEO of Immuvera Therapeutics.

Significant unmet need
There are more than 200 million dogs in Europe and the United States. Dogs develop cancer as frequently as humans, and every second dog over the age of ten gets cancer. As in humans, lung cancer is particularly difficult to treat. Today’s veterinary cancer treatment options are outdated and are either highly burdensome, insufficiently effective, or so complex that few choose to use them. Even though the total cost of treating cancer in a dog can quickly reach NOK 100,000, there is a clear and growing willingness among dog owners to pay for such treatment.

“Both dogs and dog owners deserve a gentler, more targeted, and modern alternative with fewer side effects,” says Sollid.

Proven technology and an experienced team
The drug is built on well-established technology from human medicine and follows an efficient regulatory pathway. The company is led by an experienced team with expertise in business development, regulatory strategy, clinical studies, drug manufacturing, and comparative oncology.

“Our goal is for our drug to become the first choice for treating lung cancer in dogs,” says Sollid.

Final step before launch
The capital raised will be used for the final confirmatory study required for launch in the veterinary market. The study will take the company from clinical development to strategic partnerships, acquisition, or an IPO.

“This is no longer about research, but about the final stage before launching a new medicine into the world. And who knows—if the data are striking, we may even take it back into human medicine,” Sollid concludes.

About Immuvera Therapeutics
Immuvera Therapeutics is a Norwegian biotechnology company developing an inhalation-based immunotherapy for the treatment of lung cancer in dogs. The company is built on well-established technology and collaborates with veterinary clinics and research communities to accelerate innovation. Read more at https://www.immuvera.com

Contact
CEO Jørund Sollid

+47 934 23 539

jorund.sollid@immuvera.com